Activation of Th1 and Tc1 cell adenosine A2A receptors directly inhibits IL-2 secretion in vitro and IL-2-driven expansion in vivo

Blood

Volumn 105, Issue 12, 2005, Pages 4707-4714

  Erdmann, Andreas A ^a   Gao, Zhan Guo ^a   Jung, Unsu ^a   Foley, Jason ^a   Borenstein, Todd ^a   Jacobson, Kenneth A ^a   Fowler, Daniel H ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 [4 (2 CARBOXYETHYL)PHENETHYLAMINO]ADENOSINE 5' (N ETHYLCARBOXAMIDE); ADENOSINE A1 RECEPTOR; ADENOSINE A2A RECEPTOR; ADENOSINE A2A RECEPTOR AGONIST; ADENOSINE A2B RECEPTOR; ADENOSINE A3 RECEPTOR; ALLOANTIGEN; CYCLIC AMP; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 5; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANTIGEN PRESENTING CELL; ANTIGEN SPECIFICITY; ARTICLE; CELL ACTIVATION; CELL COUNT; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOTOXIC T LYMPHOCYTE; EFFECTOR CELL; FEMALE; IN VIVO STUDY; INFLAMMATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; TH1 CELL; TH2 CELL;

EID: 20444373378     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2004-04-1407     Document Type: Article

References (33)

1. Linden J. Molecular approach to adenosine receptors: receptor-mediated mechanisms of tissue protection. Annu Rev Pharmacol Toxicol. 2001;41:775-787.
2. Fredholm BB, IJzerman AP, Jacobson KA, Klotz KN, Linden J. International Union of Pharmacology: XXV, nomenclature and classification of adenosine receptors. Pharmacol Rev. 2001;53:527-552.
3. Ohta A, Sitkovsky M. Role of G-protein-coupled adenosine receptors in downregulation of inflammation and protection from tissue damage. Nature. 2001;414:916-920.
4. Kirkpatrick P. Putting the brake on inflammation. Nat Rev Drug Discov. 2002;1:99.
5. (2A) receptor-unrelated lymphotoxicity. Br J Pharmacol. 2000;131:43-50.
6. 2A extracellular adenosine receptor-mediated signaling in adenosine-mediated inhibition of T-cell activation and expansion. Blood. 1997;90:1600-1610.
7. Carter LL, Dutton RW. Type 1 and type 2: a fundamental dichotomy for all T-cell subsets. Curr Opin Immunol. 1996;8:336-342.
8. + T cells and induce similar patterns of cytokine secretion in vitro. Int Immunol. 1995;7:891-904.
9. Nordstedt C, Fredholm BB. A modification of a protein-binding method for rapid quantification of cAMP in cell-culture supernatants and body fluid. Anal Biochem. 1990;189:231-234.
10. Post SR, Ostrom RS, Insel PA. Biochemical methods for detection and measurement of cyclic AMP and adenylyl cyclase activity. Methods Mol Biol. 2000;126:363-374.
11. Jones JF, Titus JA, Segal DM. Antibody-dependent, cell-mediated cytolysis (ADCC) with antibody-coated effectors: rat and human effectors versus tumor targets. J Immunol. 1981;126:2457-2460.
12. Young JD, Clark WR, Liu CC, Cohn ZA. A calcium- and perforin-independent pathway of killing mediated by murine cytolytic lymphocytes. J Exp Med. 1987;166:1894-1899.
13. Oshimi Y, Oda S, Honda Y, Nagata S, Miyazaki S. Involvement of Fas ligand and Fas-mediated pathway in the cytotoxicity of human natural killer cells. J Immunol. 1996;157:2909-2915.
14. 2A adenosine receptors from rat striatum and rat pheochromocytoma PC12 cells: characterization with radioligand binding and by activation of adenylate cyclase. Mol Pharmacol. 1992;41:352-359.
15. Le Gros G, Ben-Sasson SZ, Seder R, Finkelman FD, Paul WE. Generation of interleukin 4 (IL-4)-producing cells in vivo and in vitro: IL-2 and IL-4 are required for in vitro generation of IL-4-producing cells. J Exp Med. 1990;172:921-929.
16. 2 receptors in rat brain. J Pharmacol Exp Ther. 1989;251:888-893.
17. Jung U, Foley JE, Erdmann AA, Eckhaus MA, Fowler DH. CD3/CD28- costimulated T1 andT2 subsets: differential in vivo allosensitization generates distinct GVT and GVHD effects. Blood. 2003;102:3439-3446.
18. (2A) adenosine receptor: a novel therapeutic target in renal disease. Am J Physiol Renal Physiol. 2002;282:F10-18.
19. Russell JH, Ley TJ. Lymphocyte-mediated cytotoxicity. Annu Rev Immunol. 2002;20:323-370.
20. Tracey KJ, Fong Y, Hesse DG, et al. Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia. Nature. 1987;330:662-664.
21. Trinchieri G. Regulatory role of T cells producing both interteron gamma and interleukin 10 in persistent infection. J Exp Med. 2001;194:F53-57.
22. Refaeli Y, Van Parijs L, Alexander SI, Abbas AK. Interferon gamma is required for activation-induced death of T lymphocytes. J Exp Med. 2002;196:999-1005.
23. Asseman C, Mauze S, Leach MW, Coffman RL, Powrie F. An essential role for interleukin 10 in the function of regulatory T cells that inhibit intestinal inflammation. J Exp Med. 1999;190:995-1004.
24. + lymphoid engraftment. J Immunol. 1994;152:1004-1013.
25. + donor T cells fail to induce experimental acute graft-versus-host disease. J Immunol. 1995;155:585-593.
26. Hasko G, Szabo C, Nemeth ZH, Kvetan V, Pastores SM, Vizi ES. Adenosine receptor agonists differentially regulate IL-10, TNF-alpha, and nitric oxide production in RAW 264.7 macrophages and in endotoxemic mice. J Immunol. 1996;157:4634-4640.
27. Chiaramonte MG, Donaldson DD, Cheever AW, Wynn TA. An IL-13 inhibitor blocks the development of hepatic fibrosis during a T-helper type 2-dominated inflammatory response. J Clin Invest. 1999;104:777-785.
28. Lanone S, Zheng T, Zhu Z, et al. Overlapping and enzyme-specific contributions of matrix metalloproteinases-9 and -12 in IL-13-induced inflammation and remodeling. J Clin Invest. 2002;110:463-474.
29. 2A purinergic receptor-mediated signaling in murine T cells. J Biol Chem. 1997;272:25881-25889.
30. Valitutti S, Dessing M, Lanzavecchia A. Role of cAMP in regulating cytotoxic T lymphocyte adhesion and motility. Eur J Immunol. 1993;23:790-795.
31. 3 receptor. Cancer Res. 1994;54:3521-3526.
32. Via CS, Finkelman FD. Critical role of interleukin-2 in the development of acute graft-versus-host disease. Int Immunol. 1993;5:565-572.
33. Yang JC, Sherry RM, Steinberg SM, et al. Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. J Clin Oncol. 2003;21:3127-3132.